Boston Scientific gains a CE mark for MRI-safe pacing leads; PerkinElmer seals Dx marketing deal with Good Start Genetics;

@FierceMedDev: Staar got key FDA panel backing for its new ocular lens. Chances for approval now pretty high. More | Follow @FierceMedDev

@MarkHFierce: Boston Scientific gained a CE mark for new MRI-safe pacer leads. News | Follow @MarkHFierce

@MichaelGFierce: ICYMI: NeuroDerm preps for Parkinson's patch PhII trial. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Following the 5-second rule for food is like playing Russian roulette with your gut, says one molecular biologist. Article | Follow @EmilyWFierce

> Boston Scientific ($BSX) won CE-mark approval and has begun its European marketing for new MRI-compatible pacing leads. Release

> California's BioCardia won a CE mark for a device designed to enable easier navigation through vasculature during the delivery of biotherapeutics and medical devices. Release

> Germany's eZono gained a 510(k) clearance for its new tablet ultrasound system with an added feature that provides needle guidance for various procedures. Item

> New York's Vasomedical said that a subsidiary won regulatory approval in China to begin marketing its new MobiCare wireless patient monitors there. Release

> PerkinElmer ($PKI) will help expand access to in vitro fertilization tests made by Good Start Genetics in a new collaboration deal. Release

Biotech News

@FierceBiotech: ICYMI over the weekend: Chimerix started the week as a punching bag, then pulls off a TKO. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers inks a $350M deal to pair with FivePrime on immuno-oncology gold rush. Story | Follow @JohnCFierce

@DamianFierce: Amgen hits the mark in another of its 14 PhIII studies of the PCSK9-blocking evolocumab. Release | Follow @DamianFierce

@EmilyMFierce: NIH cuts, sequestration hampering cancer research. Story | Follow @EmilyMFierce

> Intercept scores a PhIII win for lead drug following Friday night frights. More

> Amgen's viral cancer vaccine T-Vec tackles melanoma tumors in PhIII. Article

Pharma News

@FiercePharma: Best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Story | Follow @FiercePharma

@TracyStaton: Tops at FiercePharma Wed.: CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients. More | Follow @TracyStaton

@EricPFierce: New twist on KV vs FDA over Makena. FDA cites compounder. News | Follow @EricPFierce

@CarlyHFierce: Going to check out South America for a few days. Talk to you Thursday, Twitterverse! | Follow @CarlyHFierce

> Bristol-Myers' Eliquis gets new FDA nod for use after ortho surgery. Article

> In latest marketing-reform move, GSK recruits in-house doctors to speak for products. More

> Shire recalls Gaucher drug but says it has plenty of supply in reserve. News

> Italian prosecutors home in on Roche, Novartis execs in eye-drug collusion probe. Story

CRO News

> Charles River snaps up Galapagos' CRO biz for $179M. News

> Clinipace dives into Asia with Choice Pharma buyout. Story

> WuXi deepens its genomics might with Illumina, Pacific Biomarkers deals. Article

> Post-merger BioClinica looks to corner the imaging market. Piece

> PPD lands a federal bioterror deal worth up to $100M. News

> Meet DPx, the result of a $2.6B CMO merger. Brief

Biotech IT News

> Illumina likely to start charging for BaseSpace storage and processing in 2014. Story

> IMS: Big Pharma must turn to tech to cut $36B from their operating costs. Article

> Public enthusiastic--but wary--about sharing personal health data. Survey

> The rise of the Silicon Valley biocomputing startup. Piece

> Drop in federal funding threatens 22 jobs at the Broad Institute. Story

> Genome data nonprofit aims to raise $25,000 through crowdfunding. Brief

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.